Arcutis Biotherapeutics Inc (ARQT)
9.31
-0.25
(-2.62%)
USD |
NASDAQ |
Jul 02, 16:00
9.26
-0.05
(-0.54%)
After-Hours: 20:00
Arcutis Biotherapeutics Research and Development Expense (TTM): 98.37M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 98.37M |
| December 31, 2023 | 110.58M |
| September 30, 2023 | 120.68M |
| June 30, 2023 | 164.17M |
| March 31, 2023 | 177.16M |
| December 31, 2022 | 182.44M |
| September 30, 2022 | 201.12M |
| June 30, 2022 | 171.99M |
| March 31, 2022 | 164.55M |
| December 31, 2021 | 145.56M |
| Date | Value |
|---|---|
| September 30, 2021 | 120.37M |
| June 30, 2021 | 112.51M |
| March 31, 2021 | 111.76M |
| December 31, 2020 | 115.31M |
| September 30, 2020 | 98.69M |
| June 30, 2020 | 78.30M |
| March 31, 2020 | 55.50M |
| December 31, 2019 | 36.52M |
| September 30, 2019 | 31.11M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
31.11M
Minimum
Sep 2019
201.12M
Maximum
Sep 2022
120.88M
Average
115.31M
Median
Dec 2020
Research and Development Expense (TTM) Benchmarks
| Heron Therapeutics Inc | 46.69M |
| Marinus Pharmaceuticals Inc | 95.57M |
| Amgen Inc | 5.069B |
| Pfizer Inc | 10.67B |
| Agios Pharmaceuticals Inc | 296.84M |